Italy's National Agency for Regional Health Services (Agenas) Names Zimmer® NexGen® LPS Knee the Most Cost-Effective Total Knee Replacement Implant
(WINTERTHUR, SWITZERLAND) December 13, 2010 -- Zimmer Holdings, Inc. (NYSE and SIX: ZMH), a leader in musculoskeletal care, today announced that the Zimmer NexGen LPS knee was ranked the most cost-effective multiradius design total knee replacement implant in Italy in a recent health technology assessment by Italy’s National Agency for Regional Health Services. 1
The assessment identified the prostheses used in Italy for total knee replacements, examined their performance based on clinical studies and arthroplasty registers and constructed a cost-effectiveness model to support buying decisions. The study collected data from 172 public hospitals and private accredited providers of the Italian National Health Service. Researchers focused on patients aged 50 and older who had received a primary implant with a minimum follow-up period of five years.
"Knee replacement surgery is a highly effective treatment that restores active lives to thousands of patients each year," said Oriol Lacorte, Vice President Marketing EMEA. "As the world’s leading provider of knee implant technologies, we are proud to receive this recognition for our NexGen LPS system which has a long history of cost-effective clinical success."
Since its introduction in 1996, Zimmer’s NexGen LPS implant has frequently been used for first-time knee replacement patients. It is a posterior stabilized implant, intended for patients who have adequate bone stock with ligaments that provide moderate joint stability or when the posterior cruciate ligament (PCL) has been cut or removed. The NexGen LPS system is part of Zimmer’s NexGen family of products, one of Zimmer’s best-selling knee brands with over one million knees implanted worldwide since its introduction. The NexGen knee system is a completely modular system. Its success is built on multiple technologies such as Prolong® Highly Crosslinked Polyethylene, Trabecular Metal™ technology, safe high-flexion designs up to 155° and anatomical fit for gender-specific needs.
For more information about the NexGen family of products, please visit www.zimmer.com
About the Company
Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer designs, develops, manufactures and markets orthopaedic reconstructive, spinal and trauma devices, dental implants, and related surgical products. Zimmer has operations in more than 25 countries around the world and sells products in more than 100 countries. Zimmer’s 2009 sales were approximately $4.1 billion. The Company is supported by the efforts of more than 8,000 employees worldwide.
1 Cerbo M., Fella D, Jefferson T, Migliore A, Paone S, Perrini MR Velardi L. Agenas HTA Report – Prostheses for primary total knee replacement in Italy. Rome, July 2009.
Zimmer Safe Harbor Statement
This press release contains forward-looking statements within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 based on current expectations, estimates, forecasts and projections about the orthopaedics industry, management’s beliefs and assumptions made by management. Forward-looking statements may be identified by the use of forward-looking terms such as "may," "will," "expects," "believes," "anticipates," "plans," "estimates," "projects," "assumes," "guides," "targets," "forecasts," and "seeks" or the negative of such terms or other variations on such terms or comparable terminology. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that could cause actual outcomes and results to differ materially. For a list and description of such risks and uncertainties, see our periodic reports filed with the U.S. Securities and Exchange Commission. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be set forth in our periodic reports. Readers of this document are cautioned not to place undue reliance on these forward-looking statements, since, while we believe the assumptions on which the forward-looking statements are based are reasonable, there can be no assurance that these forward-looking statements will prove to be accurate. This cautionary statement is applicable to all forward-looking statements contained in this document.
Paul G. Blair